Pygeum africanum

Q: What is Pygeum africanum used for?

Pygeum africanum is evaluated for the following indications with varying evidence strength: Benign prostatic hyperplasia (evidence tier C), Superfoods and adaptogens (marketing category) (evidence tier D). See the full indication matrix with dosing and citations above on this page.

Q: What are the side effects of Pygeum africanum?

Common side effects of Pygeum africanum (≥ 1 in 100): Gastrointestinal discomfort, nausea, diarrhoea, Constipation in some users, Headache, dizziness. See the Safety section for uncommon and serious reactions.

Q: Is Pygeum africanum safe during pregnancy?

FDA category N. The product is intended for men with BPH and not for women. EMA HMPC 2014 advises against use in pregnancy because of lack of data. AEMPS and AESAN advise against supplements without therapeutic indication during pregnancy.

Q: Is Pygeum africanum compatible with breastfeeding?

Not intended for women. Lactation safety has not been studied. EMA HMPC 2014 advises against use in lactation.

Q: Who should not take Pygeum africanum?

Pygeum africanum is contraindicated in: Known hypersensitivity to Prunus africana; Age under 18; Untested prostate cancer (unsupervised use masks symptoms); Concomitant anticoagulants – theoretical bleeding risk via beta-sitosterol. Full list in the Safety section.

Botanical supplement, bark extract of African plum (Prunus africana); EMA HMPC traditional-use herbal medicinal product for BPH symptoms; popular iHerb and Amazon «prostate health» category

ATC code: G04CX-PYGEUM (Pygeum (Prunus africana, bark))

Brand names – supplements

Doctor's Best Saw Palmetto + Pygeum, Life Extension Ultra Prostate Formula, Pygenil, Tadenan

Supplements are not tested in clinical trials and are not registered as medications.

Mechanism of action

Pygeum is a lipid-steroid extract from the bark of Prunus africana, an evergreen tree endemic to the equatorial African highlands. Main active compounds include phytosterols (beta-sitosterol, beta-sitosterol glucoside), pentacyclic triterpenes (ursolic and oleanolic acids) and n-docosanol. In vitro and animal data show weak partial inhibition of 5-alpha-reductase (not the level of finasteride), reduced bFGF- and EGF-driven prostatic fibroblast proliferation and suppressed leucocyte chemotaxis and leukotriene production in prostatic tissue. Clinically the effect is anti-inflammatory and antiproliferative rather than direct androgen blockade. HMPC in 2014 registered Prunus africana bark as a traditional-use herbal medicinal product for BPH symptoms based on 30 years of use, not RCTs. CITES in 1995 listed Prunus africana in Appendix II because of bark overharvesting; legal raw material requires CITES certification, and the EU and US markets are partly controlled. AEMPS and AESAN classify the product as a complemento alimenticio or as a medicamento a base de plantas depending on registration.

Indications

Benign prostatic hyperplasia

Adjunct

Pygeum is an over-the-counter herbal extract. The Cochrane Wilt review (2002) pooled 18 RCTs with 1562 men with BPH: Prunus africana extract 75-200 mg/day for 4-16 weeks moderately reduced nocturia (-19% vs placebo), improved peak urinary flow (+23%) and lowered total symptom score. The effect is modest and comparable to weak alpha-blockers in small samples; no high-quality large RCTs against tamsulosin or finasteride exist. HMPC 2014 recognises Prunus africana bark as a traditional-use medicinal product for BPH symptoms, based on 30 years of use rather than RCTs. EAU 2024, AUA 2023 and AEU 2022 recommend watchful waiting and lifestyle changes for mild BPH (IPSS <8) and alpha-blockers (tamsulosin, silodosin), 5-alpha-reductase inhibitors (finasteride, dutasteride) or combinations for moderate-severe symptoms (IPSS 8-19 and higher). Pygeum is mentioned as an option for mild symptoms or as add-on to standard therapy, not as a substitute for prescription drugs. If pygeum was prescribed or you want to try it, discuss with a urologist and have a PSA and digital rectal exam to avoid missing prostate cancer hidden behind «BPH».

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Superfoods and adaptogens (marketing category)

Not recommended

Pygeum is marketed as a «full natural replacement for finasteride and alpha-blockers», «universal prostate cancer protection», «male-pattern hair loss treatment» and «potency booster». No evidence base supports these claims. Cochrane Wilt 2002 showed a moderate symptomatic effect in BPH, not prostate cancer prevention and not androgenetic alopecia treatment. EAU 2024 and AUA 2023 agree: pygeum does not replace alpha-blockers (tamsulosin reduces IPSS by 4-6 points on average, pygeum by 1-2) and does not replace finasteride (proven prostate volume reduction of 20-25%, pygeum less than 5%). Prostate cancer prevention runs through age- and risk-based PSA screening, not supplements. Male-pattern alopecia is treated with finasteride 1 mg/day or topical minoxidil with proven efficacy. If pygeum was bought as a «replacement for drugs», untreated BPH can lead to acute urinary retention, urinary tract infections and chronic kidney injury – seek a second opinion from a urologist.

Sources

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Safety

Contraindications

Known hypersensitivity to Prunus africana
Age under 18
Untested prostate cancer (unsupervised use masks symptoms)
Concomitant anticoagulants – theoretical bleeding risk via beta-sitosterol

Serious adverse effects

Masking of prostate cancer symptoms with unsupervised use
Allergic reactions in sensitised users (rare)

Common adverse effects

Gastrointestinal discomfort, nausea, diarrhoea
Constipation in some users
Headache, dizziness

PregnancyFDA N

The product is intended for men with BPH and not for women. EMA HMPC 2014 advises against use in pregnancy because of lack of data. AEMPS and AESAN advise against supplements without therapeutic indication during pregnancy.

Breastfeeding

Not intended for women. Lactation safety has not been studied. EMA HMPC 2014 advises against use in lactation.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Pygeum africanum used for?

Pygeum africanum is evaluated for the following indications with varying evidence strength: Benign prostatic hyperplasia (evidence tier C), Superfoods and adaptogens (marketing category) (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Pygeum africanum?

Common side effects of Pygeum africanum (≥ 1 in 100): Gastrointestinal discomfort, nausea, diarrhoea, Constipation in some users, Headache, dizziness. See the Safety section for uncommon and serious reactions.

Is Pygeum africanum safe during pregnancy?

FDA category N. The product is intended for men with BPH and not for women. EMA HMPC 2014 advises against use in pregnancy because of lack of data. AEMPS and AESAN advise against supplements without therapeutic indication during pregnancy.

Is Pygeum africanum compatible with breastfeeding?

Not intended for women. Lactation safety has not been studied. EMA HMPC 2014 advises against use in lactation.

Who should not take Pygeum africanum?

Pygeum africanum is contraindicated in: Known hypersensitivity to Prunus africana; Age under 18; Untested prostate cancer (unsupervised use masks symptoms); Concomitant anticoagulants – theoretical bleeding risk via beta-sitosterol. Full list in the Safety section.

Mechanism of action

Indications

Benign prostatic hyperplasia

Adjunct

Sources

Safety

Contraindications

Known hypersensitivity to Prunus africana
Age under 18
Untested prostate cancer (unsupervised use masks symptoms)
Concomitant anticoagulants – theoretical bleeding risk via beta-sitosterol

Serious adverse effects

Masking of prostate cancer symptoms with unsupervised use
Allergic reactions in sensitised users (rare)

Common adverse effects

Gastrointestinal discomfort, nausea, diarrhoea
Constipation in some users
Headache, dizziness

PregnancyFDA N

Breastfeeding

Not intended for women. Lactation safety has not been studied. EMA HMPC 2014 advises against use in lactation.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Pygeum africanum used for?

What are the side effects of Pygeum africanum?

Is Pygeum africanum safe during pregnancy?

Is Pygeum africanum compatible with breastfeeding?

Not intended for women. Lactation safety has not been studied. EMA HMPC 2014 advises against use in lactation.

Who should not take Pygeum africanum?